Pathogenesis of pleural fibrosis

被引:81
作者
Mutsaers, SE
Prele, CM
Brody, AR
Idell, S
机构
[1] Univ Western Australia, Ctr Asthma Allergy & Resp Res, Nedlands, WA 6009, Australia
[2] Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia
[3] Tulane Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, New Orleans, LA 70118 USA
[4] Univ Texas Hlth Ctr, Tyler, TX USA
关键词
asbestos; fibrin; inflammation; mesothelium; pleural fibrosis;
D O I
10.1111/j.1440-1843.2004.00633.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pleural fibrosis resembles fibrosis in other tissues and can be defined as an excessive deposition of matrix components that results in the destruction of normal pleural tissue architecture and compromised function. Pleural fibrosis may be the consequence of an organised haemorrhagic effusion, tuberculous effusion, empyema or asbestos-related pleurisy and can manifest itself as discrete localised lesions (pleural plaques) or diffuse pleural thickening and fibrosis. Although the pathogenesis is unknown, it is likely that the complex interactions between resident and inflammatory cells, profibrotic mediators and coagulation, and fibrinolytic pathways are integral to pleural remodelling and fibrosis. It is generally considered that the primary target cell for pleural fibrosis is the subpleural fibroblast. However, increasing evidence suggests that mesothelial cells may also play a significant role in the pathogenesis of this condition, both by initiating inflammatory responses and producing matrix components. A greater understanding of the interactions between pleural and inflammatory cells, cytokines and growth factors, and blood derived proteins is required before adequate therapies can be developed to prevent pleural fibrosis from occurring.
引用
收藏
页码:428 / 440
页数:13
相关论文
共 145 条
[1]   Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation [J].
Abraham, E ;
Gyetko, MR ;
Kuhn, K ;
Arcaroli, J ;
Strassheim, D ;
Park, JS ;
Shetty, S ;
Idell, S .
JOURNAL OF IMMUNOLOGY, 2003, 170 (11) :5644-5651
[2]   Lung mesothelial cell and fibroblast responses to pleural and alveolar macrophage supernatants and to lavage fluids from crocidolite-exposed rats [J].
Adamson, IYR ;
Prieditis, H ;
Young, L .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (06) :650-656
[3]   PLEURAL FIBRINOLYTIC-ACTIVITY IS DECREASED IN INFLAMMATION AS DEMONSTRATED IN QUINACRINE PLEURODESIS TREATMENT OF MALIGNANT PLEURAL EFFUSION [J].
AGRENIUS, V ;
CHMIELEWSKA, J ;
WIDSTROM, O ;
BLOMBACK, M .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (05) :1381-1385
[4]  
[Anonymous], 1979, ASBESTOS DIS, DOI DOI 10.1136/OEM.36.2.157-B
[5]   Immunological mechanisms in pleural disease [J].
Antony, VB .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (03) :539-544
[6]   PLEURAL MESOTHELIAL CELL EXPRESSION OF C-C (MONOCYTE CHEMOTACTIC PEPTIDE) AND C-X-C (INTERLEUKIN-8) CHEMOKINES [J].
ANTONY, VB ;
HOTT, JW ;
KUNKEL, SL ;
GODBEY, SW ;
BURDICK, MD ;
STRIETER, RM .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 12 (06) :581-588
[7]   Role of iron in the cellular effects of asbestos [J].
Aust, AE ;
Lund, LG ;
Chao, CC ;
Park, SH ;
Fang, RH .
INHALATION TOXICOLOGY, 2000, 12 :75-80
[8]   CYCLOOXYGENASE ACTIVITY OF CULTURED HUMAN MESOTHELIAL CELLS [J].
BAER, AN ;
GREEN, FA .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1993, 46 (01) :37-49
[9]   Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells [J].
Bajaj, MS ;
Pendurthi, U ;
Koenig, K ;
Pueblitz, S ;
Idell, S .
EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (06) :1069-1078
[10]   STIMULATION OF INVITRO HUMAN SKIN COLLAGENASE EXPRESSION BY PLATELET-DERIVED GROWTH-FACTOR [J].
BAUER, EA ;
COOPER, TW ;
HUANG, JS ;
ALTMAN, J ;
DEUEL, TF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (12) :4132-4136